Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Kunshan Rotam Reddy Pharmaceutical is a China-based pharmaceutical company focused on the manufacture, development, and commercialization of finished-dose medicines and selected health products. The company was established as a joint venture between Rotam Group and Dr. Reddy's Laboratories and operates from Kunshan, Jiangsu, with a commercial footprint extending across multiple major Chinese cities. Its marketed portfolio spans nephrology/urology, cardiovascular, orthopedics, central nervous system, anti-allergy, and oncology-related products, and the company states it has obtained 27 drug marketing licenses. KRRP appears to be primarily a branded-generic and specialty pharma business rather than a clinical-stage biotech, with emphasis on affordable medicines, local commercialization in China, and manufacturing expansion including high-activity production capability. Public materials also indicate strategic distribution relationships with major Chinese pharma distributors and continued investment in R&D and product import/licensing for the China market.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Kunshan Rotam Reddy Pharmaceutical.